
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Br J Nutr</journal-id><journal-id journal-id-type="publisher-id">BJN</journal-id><journal-title-group><journal-title>The British Journal of Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0007-1145</issn><issn pub-type="epub">1475-2662</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">33023681</article-id><article-id pub-id-type="pmc">7578635</article-id><article-id pub-id-type="pii">S0007114520003979</article-id><article-id pub-id-type="doi">10.1017/S0007114520003979</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Papers</subject></subj-group><subj-group subj-group-type="section"><subject>Nutritional Immunology</subject></subj-group></article-categories><title-group><article-title>Vitamin K metabolism as the potential missing link between lung damage and thromboembolism in Coronavirus disease 2019</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9085-3194</contrib-id><name><surname>Janssen</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Visser</surname><given-names>Margot P. J.</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dofferhoff</surname><given-names>Anton S. M.</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vermeer</surname><given-names>Cees</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Janssens</surname><given-names>Wim</given-names></name><xref ref-type="aff" rid="a4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Walk</surname><given-names>Jona</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib></contrib-group><aff id="a1"><label>1</label>Department of Pulmonary Medicine, <institution>Canisius-Wilhelmina Hospital</institution>, <postal-code>6532 SZ</postal-code>
<city>Nijmegen</city>, <country>The Netherlands</country></aff><aff id="a2"><label>2</label>Department of Internal Medicine, <institution>Canisius-Wilhelmina Hospital</institution>, <postal-code>6532 SZ</postal-code>
<city>Nijmegen</city>, <country>The Netherlands</country></aff><aff id="a3"><label>3</label>Department of Biochemistry, Cardiovascular Research Institute Maastricht, <institution>Maastricht University</institution>, <postal-code>6229 ER</postal-code>
<city>Maastricht</city>, <country>The Netherlands</country></aff><aff id="a4"><label>4</label>Department of Respiratory Diseases, <institution>University Hospitals Leuven</institution>, <postal-code>3000</postal-code>
<city>Leuven</city>, <country>Belgium</country></aff><author-notes><corresp id="cor1"><label>*</label><bold>Corresponding author:</bold> Dr Rob Janssen, email <email>rob.janssen@cwz.nl</email></corresp></author-notes><pub-date publication-format="electronic" date-type="pub"><day>07</day><month>10</month><year>2020</year></pub-date><fpage>1</fpage><lpage>8</lpage><history><date date-type="received"><day>12</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>06</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0007114520003979a.pdf"/><abstract abstract-type="normal"><p>Coronavirus disease 2019 (Covid-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2, exerts far-reaching effects on public health and socio-economic welfare. The majority of infected individuals have mild to moderate symptoms, but a significant proportion develops respiratory failure due to pneumonia. Thrombosis is another frequent manifestation of Covid-19 that contributes to poor outcomes. Vitamin K plays a crucial role in the activation of both pro- and anticlotting factors in the liver and the activation of extrahepatically synthesised protein S which seems to be important in local thrombosis prevention. However, the role of vitamin K extends beyond coagulation. Matrix Gla protein (MGP) is a vitamin K-dependent inhibitor of soft tissue calcification and elastic fibre degradation. Severe extrahepatic vitamin K insufficiency was recently demonstrated in Covid-19 patients, with high inactive MGP levels correlating with elastic fibre degradation rates. This suggests that insufficient vitamin K-dependent MGP activation leaves elastic fibres unprotected against SARS-CoV-2-induced proteolysis. In contrast to MGP, Covid-19 patients have normal levels of activated factor II, in line with previous observations that vitamin K is preferentially transported to the liver for activation of procoagulant factors. We therefore expect that vitamin K-dependent endothelial protein S activation is also compromised, which would be compatible with enhanced thrombogenicity. Taking these data together, we propose a mechanism of pneumonia-induced vitamin K depletion, leading to a decrease in activated MGP and protein S, aggravating pulmonary damage and coagulopathy, respectively. Intervention trials should be conducted to assess whether vitamin K administration plays a role in the prevention and treatment of severe Covid-19.</p></abstract><abstract abstract-type="graphical"><p>
<fig orientation="portrait" id="d38e218" position="anchor"><graphic xlink:href="S0007114520003979_figAb"/></fig>
</p></abstract><kwd-group><title>Key words:</title><kwd>Vitamin K</kwd><kwd>Covid-19</kwd><kwd>Matrix Gla protein</kwd><kwd>Protein S</kwd><kwd>Prothrombin</kwd></kwd-group><kwd-group kwd-group-type="abbreviations"><title>Abbreviations:</title><compound-kwd><compound-kwd-part content-type="abbrev">Covid-19</compound-kwd-part><compound-kwd-part content-type="expansion">Coronavirus disease 2019</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">dp-uc</compound-kwd-part><compound-kwd-part content-type="expansion">desphospho-uncarboxylated</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">MGP</compound-kwd-part><compound-kwd-part content-type="expansion">matrix Gla protein</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">SARS-CoV</compound-kwd-part><compound-kwd-part content-type="expansion">severe acute respiratory syndrome coronavirus</compound-kwd-part></compound-kwd><compound-kwd><compound-kwd-part content-type="abbrev">VKA</compound-kwd-part><compound-kwd-part content-type="expansion">vitamin K antagonist</compound-kwd-part></compound-kwd></kwd-group><counts><fig-count count="4"/><ref-count count="77"/><page-count count="8"/></counts></article-meta></front><body><p>Coronavirus disease 2019 (Covid-19) is an infectious disorder caused by the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 that emerged from the Chinese city of Wuhan at the end of 2019 and has since then relentlessly spread across the globe<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup>. The Covid-19 pandemic is causing a worldwide medical and socio-economic crisis of unprecedented proportions in modern times. The vast majority of individuals who contract SARS-CoV-2 have mild to moderate symptoms. However, a significant minority develops respiratory failure due to pneumonia and/or acute respiratory distress syndrome<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup>.</p><p>Particularly, SARS-CoV-2-infected individuals suffering from certain premorbid conditions, such as hypertension, diabetes, CVD and obesity, are at increased risk of complicated disease course<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup>. Although these conditions are also associated with poor outcomes due to other infectious diseases, precisely why these groups have high morbidity and mortality is currently unknown. We made the observation that these disorders are associated with elastic fibre pathologies as well as vitamin K insufficiency.</p><p>Thromboembolism and generalised microvascular thrombosis are also prevalent in severe Covid-19<sup>(<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>)</sup>. The mechanisms leading from pulmonary infection to systemic coagulopathy in Covid-19 have not yet been entirely elucidated. It has previously been shown that severe vitamin K deficiency in critically ill patients can be misdiagnosed as disseminated intravascular coagulation<sup>(<xref rid="r4" ref-type="bibr">4</xref>)</sup>. Given the importance of vitamin K-dependent proteins in coagulation as well as elastic fibre metabolism, we recently hypothesised that vitamin K is implicated in Covid-19 pathogenesis and could represent the missing link between pulmonary damage and thrombogenicity.</p><sec sec-type="other" id="s1"><title>Vitamin K metabolism</title><p>Vitamin K is a monofunctional nutrient from a biochemical perspective as its only well-described function is facilitating &#x003b3;-carboxylation. However, it can be regarded as pleiotropic because it activates proteins with distinct, opposing and not yet fully unravelled functions.</p><p>Vitamin K catalyses the carboxylation reaction that transforms glutamic acid into &#x003b3;-carboxyglutamic (Gla) residues and is well known as an activator of hepatic procoagulant factors II (prothrombin), VII, IX and X. However, vitamin K also activates anticoagulant proteins C and S as well as a number of extrahepatic proteins not involved in blood coagulation.</p><sec id="s1-1" sec-type="other"><title>Endothelial protein S</title><p>Contrary to other vitamin K-dependent procoagulant factors and protein C, which are almost exclusively hepatic proteins, about 50 % of anticoagulant protein S is produced outside the liver<sup>(<xref rid="r5" ref-type="bibr">5</xref>)</sup>. This part of protein S is mainly synthesised in endothelial cells and thought to play an important role in the local prevention of thrombosis<sup>(<xref rid="r5" ref-type="bibr">5</xref>&#x02013;<xref rid="r7" ref-type="bibr">7</xref>)</sup>. Endothelium-produced protein S has the ability to associate with the cell surface and promote procoagulant factor V inactivation in the presence of activated protein C<sup>(<xref rid="r7" ref-type="bibr">7</xref>)</sup>.</p></sec><sec id="s1-2" sec-type="other"><title>Matrix Gla protein</title><p>Vitamin K-dependent matrix Gla protein (MGP) has been extensively studied as an inhibitor of vascular mineralisation<sup>(<xref rid="r8" ref-type="bibr">8</xref>)</sup>; however, its role in the pulmonary compartment seems to be comparable<sup>(<xref rid="r9" ref-type="bibr">9</xref>)</sup>. Besides preventing soft tissue calcification, MGP also protects against elastic fibre degradation. This was demonstrated in MGP knockout mice, which developed severely mineralised as well as fragmented elastic fibres<sup>(<xref rid="r10" ref-type="bibr">10</xref>)</sup>.</p><p>Elastic fibres are critical components in the extracellular matrix of dynamic tissues<sup>(<xref rid="r11" ref-type="bibr">11</xref>)</sup>. They provide deformability to lungs and arteries, which facilitates respiration and circulation<sup>(<xref rid="r11" ref-type="bibr">11</xref>)</sup>. Initial elastic fibre development is almost exclusively restricted to the perinatal period<sup>(<xref rid="r11" ref-type="bibr">11</xref>)</sup>. Elastic fibre degradation and repair, however, are continuous processes<sup>(<xref rid="r11" ref-type="bibr">11</xref>)</sup>. The balance between the two is delicate and of vital importance for cardiovascular and pulmonary health<sup>(<xref rid="r12" ref-type="bibr">12</xref>)</sup>. The rate of proteolytic elastic fibre degradation increases during ageing<sup>(<xref rid="r13" ref-type="bibr">13</xref>)</sup>. This age-related acceleration of elastolysis is enhanced in certain pulmonary conditions such as chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis<sup>(<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>)</sup>.</p><p>Affinity of elastic fibres for Ca is high<sup>(<xref rid="r15" ref-type="bibr">15</xref>)</sup>. Critically, elastic fibre calcification and proteolytic degradation processes are closely related. Partially degraded elastic fibres are more negatively charged, attracting positively charged Ca<sup>(<xref rid="r15" ref-type="bibr">15</xref>)</sup>. As elastic fibre Ca content increases, the synthesis of matrix metalloproteinases, proteolytic enzymes that degrade elastin fibres, is also up-regulated<sup>(<xref rid="r16" ref-type="bibr">16</xref>)</sup>. Peri-arterial application of Ca on rat abdominal aortas induces both calcification and proteolytic degradation of elastic fibres<sup>(<xref rid="r17" ref-type="bibr">17</xref>)</sup>. Subdermal implantation of elastin in rats results in significant calcification, but local application of a protease inhibitor attenuates this mineralisation<sup>(<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>)</sup>. MGP plays a critical role in the protection of elastic tissues against mineralisation<sup>(<xref rid="r10" ref-type="bibr">10</xref>)</sup>, most likely because other proteins that inhibit calcification (e.g. fetuin-A) are too large to enter the lumen of the fibres<sup>(<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r20" ref-type="bibr">20</xref>)</sup>.</p></sec><sec id="s1-3" sec-type="other"><title>Vitamin K recycling</title><p>Storage capacity of vitamin K is limited, and therefore, its metabolism must be very efficient. After being oxidised during the carboxylation reaction, vitamin K is reactivated repeatedly by the enzyme vitamin K epoxide reductase in the vitamin K cycle (<xref ref-type="fig" rid="f1">Fig. 1</xref>)<sup>(<xref rid="r21" ref-type="bibr">21</xref>)</sup>. Nevertheless, insufficiency may develop within days of poor intake, particularly in pathological states of increased vitamin K utilisation<sup>(<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r22" ref-type="bibr">22</xref>)</sup>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Vitamin K cycle. The vitamin K cycle and the effects of vitamin K antagonists. <inline-graphic xlink:href="S0007114520003979_inline1.jpg" mime-subtype="png" mimetype="image"/>, Active; <inline-graphic xlink:href="S0007114520003979_inline2.jpg" mime-subtype="png" mimetype="image"/>, inactive.</p></caption><graphic xlink:href="S0007114520003979_fig1"/></fig>
</p></sec><sec id="s1-4" sec-type="other"><title>Triage-based distribution</title><p>The triage theory posits that during times of scarcity, micronutrients are reserved for use in processes that form the greatest threat to short-term survival if not properly executed<sup>(<xref rid="r23" ref-type="bibr">23</xref>)</sup>. This implies that in case of vitamin K insufficiency, the vitamin is preferentially transported to the liver for the activation of the above-mentioned procoagulant factors at the expense of extrahepatic vitamin K-dependent proteins such as MGP (<xref ref-type="fig" rid="f2">Fig. 2</xref>).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Micronutrient triage theory with regard to vitamin K. Particularly vitamin K<sub>1</sub> is preferentially transported to the liver. This implies that the grade of carboxylation in a state of vitamin K deficiency is usually higher for hepatic procoagulant factors, such as factor II, than for endothelial protein S as well as for pulmonary matrix Gla protein (MGP).</p></caption><graphic xlink:href="S0007114520003979_fig2"/></fig>
</p><p>This was demonstrated in women between 60 and 80 years old who consumed a vitamin K<sub>1</sub>-deficient diet for 28 d. Undercarboxylated osteocalcin, a vitamin K-dependent bone protein, increased almost immediately, whereas undercarboxylated factor II increased more slowly<sup>(<xref rid="r24" ref-type="bibr">24</xref>)</sup>. Moreover, when patients using vitamin K antagonists (VKA) as anticoagulants steadily increased their dietary intake of vitamin K<sub>1</sub>, a significant decrease in undercarboxylated factor II was seen at 150 &#x003bc;g/d, while a significant decrease in undercarboxylated osteocalcin was only seen at an intake of 300 &#x003bc;g/d<sup>(<xref rid="r25" ref-type="bibr">25</xref>)</sup>.</p><p>Similar to osteocalcin and MGP, vitamin K insufficiency would result in deficient activation of endothelial protein S before causing a decrease in carboxylated procoagulant factors (<xref ref-type="fig" rid="f2">Fig. 2</xref>)<sup>(<xref rid="r26" ref-type="bibr">26</xref>)</sup>. This could explain the seemingly paradoxical increase of thrombosis risk in the first week of treatment with VKA<sup>(<xref rid="r27" ref-type="bibr">27</xref>)</sup>.</p><p>Although the biological function of vitamins K<sub>1</sub> and K<sub>2</sub> is similar, there are differences with regard to bioavailability and tissue distribution. Half-life times of most K<sub>2</sub> vitamins are longer than that of K<sub>1</sub>, and vitamin K<sub>2</sub> may have more extrahepatic potential than K<sub>1</sub>
<sup>(<xref rid="r28" ref-type="bibr">28</xref>)</sup>. Vitamin K<sub>1</sub> is found in green vegetables such as broccoli, spinach and kale. Certain bacteria have the ability to produce vitamin K<sub>2</sub>. It is therefore present in fermented food products such as cheese, curd and sauerkraut as well as in certain fishes.</p></sec><sec id="s1-5" sec-type="other"><title>Assessment of vitamin K status</title><p>Measuring circulating levels of the two naturally occurring forms of vitamin K &#x02013; vitamin K<sub>1</sub> (phylloquinone) and K<sub>2</sub> (the group of menaquinones) &#x02013; is technically feasible<sup>(<xref rid="r29" ref-type="bibr">29</xref>)</sup>. However, the value of such measurements for assessing general vitamin K status is limited. Quantification of vitamin K-dependent proteins that have not been carboxylated, on the other hand, is a valuable method reflecting the combined functional deficit of vitamin K<sub>1</sub> and K<sub>2</sub>
<sup>(<xref rid="r29" ref-type="bibr">29</xref>)</sup>. Determination of desphospho-uncarboxylated (dp-uc; i.e. inactive) MGP levels and the ratio between uncarboxylated and carboxylated osteocalcin are validated assays of extrahepatic vitamin K status<sup>(<xref rid="r29" ref-type="bibr">29</xref>)</sup>.</p><p>High dp-ucMGP reflects low vitamin K status and <italic>vice versa</italic>. Although increasing vitamin K consumption decreases dp-ucMGP<sup>(<xref rid="r30" ref-type="bibr">30</xref>&#x02013;<xref rid="r32" ref-type="bibr">32</xref>)</sup>, its levels are not simply a biomarker of vitamin K intake but depend on other factors as well. Circulating dp-ucMGP concentration can best be regarded as a reflection of the total extrahepatic vitamin K deficit, that is, the amount of vitamin K that is needed to carboxylate all the uncarboxylated vitamin K-dependent proteins in the body<sup>(<xref rid="r33" ref-type="bibr">33</xref>)</sup>.</p><p>Hepatic vitamin K status is usually quantified by measuring levels of protein induced by vitamin K absence (PIVKA)-II (i.e. uncarboxylated prothrombin)<sup>(<xref rid="r24" ref-type="bibr">24</xref>)</sup>.</p></sec></sec><sec sec-type="other" id="s2"><title>Vitamin K metabolism in Coronavirus disease 2019</title><p>Extrahepatic vitamin K status is severely reduced in Covid-19 patients, reflected by elevated dp-ucMGP levels<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>. Reasons for this could include premorbid low vitamin K status in combination with accelerated utilisation during infection.</p><sec id="s2-1" sec-type="other"><title>Vitamin K status in co-morbidities associated with poor Coronavirus disease 2019 outcomes</title><p>dp-ucMGP levels are elevated in various diseases that are associated with elastic fibre calcification and degradation such as diabetes<sup>(<xref rid="r35" ref-type="bibr">35</xref>)</sup>, hypertension<sup>(<xref rid="r36" ref-type="bibr">36</xref>)</sup>, CVD<sup>(<xref rid="r37" ref-type="bibr">37</xref>)</sup>, chronic kidney disease<sup>(<xref rid="r35" ref-type="bibr">35</xref>,<xref rid="r38" ref-type="bibr">38</xref>)</sup> and obesity<sup>(<xref rid="r39" ref-type="bibr">39</xref>)</sup>. It is possible that reduced vitamin K intake increases the risk of developing these conditions<sup>(<xref rid="r40" ref-type="bibr">40</xref>)</sup>. However, increased vitamin K demand due to enhanced utilisation may be another important cause of high dp-ucMGP<sup>(<xref rid="r41" ref-type="bibr">41</xref>)</sup>. Partially degraded and mineralised elastic fibres &#x02013; which are prevalent in diabetic, hypertensive, renal and cardiovascular patients &#x02013; are more vulnerable to further proteolysis and calcification<sup>(<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r42" ref-type="bibr">42</xref>)</sup>. This increases the need for MGP synthesis to protect elastic fibres<sup>(<xref rid="r9" ref-type="bibr">9</xref>)</sup>, draining vitamin K stores for MGP carboxylation and leading to higher dp-ucMGP levels.</p><p>In vascular diseases<sup>(<xref rid="r40" ref-type="bibr">40</xref>)</sup>, as well as in the general population<sup>(<xref rid="r43" ref-type="bibr">43</xref>,<xref rid="r44" ref-type="bibr">44</xref>)</sup>, increased dp-ucMGP levels associate with higher all-cause mortality. Vitamin K supplementation reduces dp-ucMGP levels and has a favourable effect on progression of clinically relevant endpoints, including aortic valve calcification, arterial stiffness and bone loss<sup>(<xref rid="r30" ref-type="bibr">30</xref>&#x02013;<xref rid="r32" ref-type="bibr">32</xref>)</sup>.</p></sec><sec id="s2-2" sec-type="other"><title>Vitamin K insufficiency in the pathogenesis of Coronavirus disease 2019</title><p>We propose a series of sequential pathological steps occurring in response to SARS-CoV-2 infection that are responsible for up-regulation of MGP expression and extrahepatic vitamin K depletion, leading to pulmonary damage and thrombosis in Covid-19 (<xref ref-type="fig" rid="f3">Fig. 3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>Proposed sequential steps linking severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumonia to vitamin K insufficiency, pulmonary damage and thrombogenecity. (1) SARS-CoV-2 enters alveolar type II (ATII) cells. (2) Infected AT2 cells response by up-regulating synthesis of proinflammatory cytokines, including IL-6. (3) This leads to an increase in the number and activation of alveolar macrophages (4) that produce matrix metalloproteinases (MMP), which accelerates degradation of elastic fibres. (5) The increased polarity of partially degraded elastic fibres (6) enhances their affinity for calcium and leads to increased elastic fibre calcium content. (7) Matrix Gla protein (MGP) synthesis is up-regulated in an attempt to protect elastic fibres from calcification and degradation, (8) and the need for vitamin K to carboxylate additional MGP increases. (9) This increased utilisation of vitamin K may induce extrahepatic vitamin K insufficiency, (10a) leading to insufficient carboxylation of pulmonary MGP and (11a) increased pulmonary damage. (10b) The second consequence of extrahepatic vitamin K insufficiency is decreased carboxylation of endothelial protein S, (11b) which increases thrombosis risk.</p></caption><graphic xlink:href="S0007114520003979_fig3"/></fig>
</p><p>Infection primarily begins through the inhalation of SARS-CoV-2-containing aerosols. The virus&#x02019; so-called &#x02018;spike proteins&#x02019; have the ability of binding to angiotensin-converting enzyme 2 receptors, which enables viral entry into human cells, including alveolar type II cells. These proteins are also the most immunogenic part of the virus<sup>(<xref rid="r45" ref-type="bibr">45</xref>)</sup>.</p><p>Although Covid-19 is a communicable disease, morbidity and mortality are mainly attributable to immunological rather than direct infectious complications. SARS-CoV-2 has the ability to put the immune system of infected individuals into overdrive resulting in a hyperinflammatory pulmonary state<sup>(<xref rid="r46" ref-type="bibr">46</xref>)</sup>. Data from SARS infections suggest that the synthesis of proinflammatory cytokines begins in infected alveolar type II cells<sup>(<xref rid="r47" ref-type="bibr">47</xref>)</sup>. Increased levels of IL-6 and TNF-&#x003b1; are associated with poor Covid-19 outcome<sup>(<xref rid="r48" ref-type="bibr">48</xref>)</sup>. Autopsy studies consistently implicate infiltrating lymphocytes and macrophages as further drivers of pulmonary inflammation during Covid-19<sup>(<xref rid="r49" ref-type="bibr">49</xref>,<xref rid="r50" ref-type="bibr">50</xref>)</sup>. Importantly, a specific subset of macrophages appears in the lungs of Covid-19 patients<sup>(<xref rid="r51" ref-type="bibr">51</xref>)</sup>, which has previously been demonstrated to produce matrix metalloproteinases-9 in patients with idiopathic pulmonary fibrosis<sup>(<xref rid="r52" ref-type="bibr">52</xref>)</sup>.</p><p>Upon SARS-CoV-2 infection, elastic fibre breakdown accelerates compared with degradation rates in age-matched controls<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>. High pulmonary concentrations of matrix metalloproteinases-9 or other proteases produced either by infiltrating or locally proliferating macrophages could be an explanation for this<sup>(<xref rid="r51" ref-type="bibr">51</xref>,<xref rid="r52" ref-type="bibr">52</xref>)</sup>. A significant correlation between dp-ucMGP and the rate of elastic fibre degradation was observed in Covid-19 patients<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>. We suspect that accelerated elastic fibre degradation due to enhanced proteolytic activity in SARS-CoV-2-infected lungs increases elastic fibre vulnerability to Ca, leading to an up-regulation of MGP synthesis and depletion of extrahepatic vitamin K stores. This shortage impairs MGP activation, presumably causing further elastic fibre damage, and elevation of circulating dp-ucMGP. The rate of elastic fibre degradation associates with poor outcome in patients with SARS-CoV-2 pneumonia<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>, as it does in other pulmonary diseases such as chronic obstructive pulmonary disease, cystic fibrosis and bronchiectasis<sup>(<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r53" ref-type="bibr">53</xref>,<xref rid="r54" ref-type="bibr">54</xref>)</sup>.</p><p>Conditions associated with chronic elastic fibre pathology, including diabetes, hypertension and CVD, are also related to worse prognosis of SARS-CoV-2 infection. Recent data demonstrated that Covid-19 patients with poor outcomes had increased thoracic aortic and coronary artery calcification on computed tomography scan, though these analyses lost significance after correction for age and sex<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>. Nevertheless, pre-existing elastic fibre damage predisposes to enhanced proteolytic degradation during inflammation<sup>(<xref rid="r42" ref-type="bibr">42</xref>)</sup>, potentially explaining the increased severity of Covid-19 in those populations.</p><p>We further theorise that vitamin K depletion also has a key effect on another characteristic disease manifestation of Covid-19. Though dp-ucMGP is elevated in Covid-19, hepatic procoagulant vitamin K status, quantified by measuring PIVKA-II, was hardly affected<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>. According to the micronutrient triage theory<sup>(<xref rid="r23" ref-type="bibr">23</xref>)</sup>, the preferential activation of hepatic over extrahepatic proteins and the fact that about 50 % of protein S synthesis occurs in endothelial cells imply that the uncarboxylated protein S fraction would also be increased<sup>(<xref rid="r6" ref-type="bibr">6</xref>)</sup>. This could increase the risk of thrombosis. Consumption of clotting factors during thrombosis puts a further burden on vitamin K stores by increasing demand for activation of newly synthesised coagulation factors to replace used ones<sup>(<xref rid="r55" ref-type="bibr">55</xref>)</sup>. With preference given to the carboxylation of procoagulant factors, progressive depletion of active endothelial protein S increasingly skews the balance towards coagulation.</p></sec><sec id="s2-3" sec-type="other"><title>Interaction between vitamins D and K</title><p>Vitamin D is both endogenously produced in the skin and exogenously acquired from food. Intake of vitamins D and K is correlated due to their co-presence in various food sources. Both vitamin D and K deficiencies are prevalent around the world. Contrary to vitamin K, however, assessment of vitamin D status and propagation of vitamin D supplementation are widespread.</p><p>A meta-analysis conducted prior to the emergence of SARS-CoV-2 demonstrated that daily or weekly vitamin D supplementation reduced the risk of acute respiratory tract infection<sup>(<xref rid="r56" ref-type="bibr">56</xref>)</sup>. The role of vitamin D in susceptibility to SARS-CoV-2 infection has been assessed by various groups, and to date, results appear to be conflicting<sup>(<xref rid="r57" ref-type="bibr">57</xref>&#x02013;<xref rid="r59" ref-type="bibr">59</xref>)</sup>. Studies evaluating the modulatory role of vitamin D on disease severity in Covid-19 have not yet been reported. Vitamin D has anti-inflammatory and anti-proteolytic properties<sup>(<xref rid="r60" ref-type="bibr">60</xref>&#x02013;<xref rid="r62" ref-type="bibr">62</xref>)</sup>, which may potentially be favourable in Covid-19. Increasing vitamin D intake is generally regarded to be safe<sup>(<xref rid="r63" ref-type="bibr">63</xref>)</sup>, although clinical data are limited. Due to tight hormonal regulation, serum Ca levels are hardly and at most transiently increased even after high-dose vitamin D administration<sup>(<xref rid="r64" ref-type="bibr">64</xref>)</sup>. However, short-term hypercalcaemia may induce deposition of Ca on elastic fibres, which is not necessarily released from fibres after normalisation of systemic Ca levels<sup>(<xref rid="r64" ref-type="bibr">64</xref>)</sup>. High-dose vitamin D administration in rats depletes extrahepatic vitamin K stores by strongly up-regulating MGP synthesis leading to acceleration of elastic fibre calcification and degradation<sup>(<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r64" ref-type="bibr">64</xref>)</sup>. Vitamin D administration in a state of vitamin K deficiency may thereby endanger pulmonary and vascular health. There is also human data that raised these concerns. Vitamin D supplementation was associated with premature mortality in vitamin K-insufficient stable kidney transplant recipients<sup>(<xref rid="r65" ref-type="bibr">65</xref>)</sup>. It may therefore be prudent to first supplement vitamin K in invariably vitamin K-insufficient Covid-19 hospitalised patients and to start vitamin D supplementation in those who are vitamin D-deficient only when extrahepatic vitamin K status has been restored<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>.</p><p>Furthermore, vitamin K might be a useful additive to vitamin D because there is some evidence that it can act as an anti-inflammatory agent by suppressing NF-<italic>&#x003ba;</italic>B signal transduction. It may also exert a protective effect against oxidative stress by blocking the generation of reactive oxygen species<sup>(<xref rid="r66" ref-type="bibr">66</xref>)</sup>.</p></sec><sec id="s2-4" sec-type="other"><title>Vitamin K antagonists</title><p>Although progressively substituted by direct oral anticoagulants, VKA remain important drugs for the prevention of venous and arterial thrombosis. VKA exert their antithrombotic function through inhibition of vitamin K 2,3-epoxide reductase complex 1, thereby interrupting the vitamin K cycle and inducing vitamin K deficiency (<xref ref-type="fig" rid="f1">Fig. 1</xref>). This obstructs carboxylation of hepatic procoagulant factors, which delays blood clotting.</p><p>Remarkably, it has been reported that within the epicentre of the Covid-19 outbreak in the UK, the OR of having a supra-therapeutic anticoagulation with VKA (i.e. international normalised ratio &#x0003e; 8&#x000b7;0) was 6&#x000b7;3 around the lockdown date compared with the same period in the year before<sup>(<xref rid="r67" ref-type="bibr">67</xref>)</sup>. Root cause analysis suggested that at least 50 % of these elevations were related to Covid-19<sup>(<xref rid="r67" ref-type="bibr">67</xref>)</sup>. Although the majority of possible/confirmed Covid-19 cases had used antibiotics which may influence INR<sup>(<xref rid="r68" ref-type="bibr">68</xref>)</sup>, we speculate that enhanced pulmonary vitamin K utilisation during SARS-CoV-2 pneumonia could also disturb the narrow therapeutic balance between VKA dosage and vitamin K intake levels.</p><p>VKA use in idiopathic pulmonary fibrosis patients associates with reduced survival<sup>(<xref rid="r69" ref-type="bibr">69</xref>)</sup>, and it has been suggested that this effect of VKA may be very acute<sup>(<xref rid="r70" ref-type="bibr">70</xref>)</sup>. There are reasons to suspect that vitamin K-dependent MGP activation is already compromised in both animals and humans with fibrotic lung disease and that this is further compromised by VKA administration<sup>(<xref rid="r71" ref-type="bibr">71</xref>,<xref rid="r72" ref-type="bibr">72</xref>)</sup>. Other potential mechanisms by which VKA could exacerbate lung fibrosis may be via preventing anticoagulant protein C and S activation, which both have antifibrotic properties<sup>(<xref rid="r73" ref-type="bibr">73</xref>,<xref rid="r74" ref-type="bibr">74</xref>)</sup>. Through these mechanisms, VKA may also have an unfavourable effect on pneumonia severity in Covid-19 patients; however, this has not yet been evaluated.</p><p>VKA may also have potentially favourable effects on disease course of Covid-19 by prevention of thrombosis, as has been shown for heparins<sup>(<xref rid="r75" ref-type="bibr">75</xref>)</sup>. However, considering the consequences of vitamin K insufficiency for pulmonary disease<sup>(<xref rid="r69" ref-type="bibr">69</xref>,<xref rid="r70" ref-type="bibr">70</xref>)</sup>, it may be worthwhile to conduct a study comparing the risk of severe Covid-19 in patients on VKA with those using other classes of anticoagulant medications, provided the availability of a sufficiently large cohort to correct for confounding factors.</p></sec></sec><sec sec-type="other" id="s3"><title>Future perspective</title><p>There is a need for further experimental evidence to link vitamin K deficiency with the pathology of Covid-19 and determine whether vitamin K supplementation has a place in treatment protocols.</p><p>First, there is need for lung-specific data. The current data on vitamin K status in Covid-19 are confined to measurement of circulating parameters, and we were unable to distinguish pulmonary from systemic elastic fibre degradation<sup>(<xref rid="r34" ref-type="bibr">34</xref>)</sup>. Autopsy studies performed on Covid-19 patients could shed light on the presence of carboxylated and uncarboxylated vitamin K-dependent proteins at sites of SARS-CoV-2-related lung disease. This could give support to our hypothesis of increased pulmonary MGP expression and enhanced vitamin K utilisation. Animal models may also be used to elucidate the effect of vitamin K insufficiency, administration and antagonism specifically on pathologies of pulmonary elastic fibres.</p><p>Second, it is important to confirm that protein S activity is decreased during vitamin K insufficiency in Covid-19. This could be explored by measuring protein S activity, but this method has potential confounders<sup>(<xref rid="r76" ref-type="bibr">76</xref>)</sup>. An alternative would be to quantify undercarboxylated protein S either with targeted antibodies or using liquid chromatography-tandem MS; however, to our knowledge, such assays have yet to be developed.</p><p>Finally, there is need for human intervention studies to determine whether vitamin K supplementation has a place in the prevention and treatment of severe Covid-19. Clinical trials assessing vitamin K administration in hospitalised populations are needed to evaluate both safety and efficacy. The safety of even high doses of vitamin K has been established in healthy persons<sup>(<xref rid="r77" ref-type="bibr">77</xref>)</sup> but remains to be assessed in severely ill Covid-19 patients. The potential role of vitamin K supplementation to prevent development of severe Covid-19 in subjects who have not yet contracted SARS-CoV-2, but are at risk for the infection, is also very relevant to assess.</p><p>In conclusion, the potential role of vitamin K supplementation to prevent the development and progression of severe Covid-19 remains largely unexplored. We would argue that the impact of the current crisis warrants thorough evaluation of the therapeutic potential of vitamin K in Covid-19 pathogenesis for two key reasons. Unlike other treatment strategies currently under development for Covid-19 such as dexamethasone, vitamin K does not have any known unfavourable effects in those who do not use VKA. Furthermore, it is relatively simple and inexpensive to manufacture contrary to other therapies like remdesivir or convalescent plasma. Taken together this means that effectiveness can be rapidly and cheaply evaluated in clinical trials and easily implemented if proven successful.</p></sec></body><back><ack><title>Acknowledgements</title><p>This work was funded by Kappa Bioscience AS, a manufacturer of vitamin K<sub>2</sub> (MK-7).</p><p>R. J. developed the theory. R. J., M. P. J. V. and J. W. wrote the first draft of the manuscript. A. S. M. D., C. V. and W. J. critically revised the manuscript.</p><p>R. J. discloses application of a patent on vitamin K in Covid-19. R. J. and J. W. have a scientific collaboration with Kappa Bioscience AS, a manufacturer of vitamin K<sub>2</sub> (MK-7). M. P. J. V., A. S. M. D., C. V. and W. J. declare no competing interests.</p></ack><ref-list id="reflist1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal" id="r1">
<string-name>
<surname>Huang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>497</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal" id="r2">
<string-name>
<surname>Tang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title>. <source>J Thromb Haemost</source>
<volume>18</volume>, <fpage>844</fpage>&#x02013;<lpage>847</lpage>.<pub-id pub-id-type="pmid">32073213</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal" id="r3">
<string-name>
<surname>Cui</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia</article-title>. <source>J Thromb Haemost</source>
<volume>18</volume>, <fpage>1421</fpage>&#x02013;<lpage>1424</lpage>.<pub-id pub-id-type="pmid">32271988</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal" id="r4">
<string-name>
<surname>Alperin</surname>
<given-names>JB</given-names>
</string-name> (<year>1987</year>) <article-title>Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients</article-title>. <source>JAMA</source>
<volume>258</volume>, <fpage>1916</fpage>&#x02013;<lpage>1919</lpage>.<pub-id pub-id-type="pmid">3656602</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal" id="r5">
<string-name>
<surname>Burstyn-Cohen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Heeb</surname>
<given-names>MJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Lemke</surname>
<given-names>G</given-names>
</string-name> (<year>2009</year>) <article-title>Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis</article-title>. <source>J Clin Invest</source>
<volume>119</volume>, <fpage>2942</fpage>&#x02013;<lpage>2953</lpage>.<pub-id pub-id-type="pmid">19729839</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal" id="r6">
<string-name>
<surname>Fair</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Marlar</surname>
<given-names>RA</given-names>
</string-name> &#x00026; <string-name>
<surname>Levin</surname>
<given-names>EG</given-names>
</string-name> (<year>1986</year>) <article-title>Human endothelial cells synthesize protein S</article-title>. <source>Blood</source>
<volume>67</volume>, <fpage>1168</fpage>&#x02013;<lpage>1171</lpage>.<pub-id pub-id-type="pmid">2937470</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal" id="r7">
<string-name>
<surname>Stern</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Brett</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>K</given-names>
</string-name>, <etal>et al.</etal> (<year>1986</year>) <article-title>Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S</article-title>. <source>J Cell Biol</source>
<volume>102</volume>, <fpage>1971</fpage>&#x02013;<lpage>1978</lpage>.<pub-id pub-id-type="pmid">2939094</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal" id="r8">
<string-name>
<surname>Schurgers</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Uitto</surname>
<given-names>J</given-names>
</string-name> &#x00026; <string-name>
<surname>Reutelingsperger</surname>
<given-names>CP</given-names>
</string-name> (<year>2013</year>) <article-title>Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization</article-title>. <source>Trends Mol Med</source>
<volume>19</volume>, <fpage>217</fpage>&#x02013;<lpage>226</lpage>.<pub-id pub-id-type="pmid">23375872</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal" id="r9">
<string-name>
<surname>Price</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Buckley</surname>
<given-names>JR</given-names>
</string-name> &#x00026; <string-name>
<surname>Williamson</surname>
<given-names>MK</given-names>
</string-name> (<year>2001</year>) <article-title>The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats</article-title>. <source>J Nutr</source>
<volume>131</volume>, <fpage>2910</fpage>&#x02013;<lpage>2915</lpage>.<pub-id pub-id-type="pmid">11694617</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal" id="r10">
<string-name>
<surname>Luo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ducy</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McKee</surname>
<given-names>MD</given-names>
</string-name>, <etal>et al.</etal> (<year>1997</year>) <article-title>Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein</article-title>. <source>Nature</source>
<volume>386</volume>, <fpage>78</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">9052783</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal" id="r11">
<string-name>
<surname>Mithieux</surname>
<given-names>SM</given-names>
</string-name> &#x00026; <string-name>
<surname>Weiss</surname>
<given-names>AS</given-names>
</string-name> (<year>2005</year>) <article-title>Elastin</article-title>. <source>Adv Protein Chem</source>
<volume>70</volume>, <fpage>437</fpage>&#x02013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">15837523</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal" id="r12">
<string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, <etal>et al.</etal> (<year>2004</year>) <article-title>Elastic fiber homeostasis requires lysyl oxidase-like 1 protein</article-title>. <source>Nat Genet</source>
<volume>36</volume>, <fpage>178</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">14745449</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal" id="r13">
<string-name>
<surname>Rabinovich</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Wrobel</surname>
<given-names>K</given-names>
</string-name>, <etal>et al.</etal> (<year>2016</year>) <article-title>Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD</article-title>. <source>Eur Respir J</source>
<volume>47</volume>, <fpage>1365</fpage>&#x02013;<lpage>1373</lpage>.<pub-id pub-id-type="pmid">27009168</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal" id="r14">
<string-name>
<surname>Huang</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Bolton</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>BE</given-names>
</string-name>, <etal>et al.</etal> (<year>2016</year>) <article-title>Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease</article-title>. <source>Eur Respir J</source>
<volume>48</volume>, <fpage>1215</fpage>&#x02013;<lpage>1218</lpage>.<pub-id pub-id-type="pmid">27587547</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal" id="r15">
<string-name>
<surname>Rucker</surname>
<given-names>RB</given-names>
</string-name> (<year>1974</year>) <article-title>Calcium binding to elastin</article-title>. <source>Adv Exp Med Biol</source>
<volume>48</volume>, <fpage>185</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">4372871</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal" id="r16">
<string-name>
<surname>Lee</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Basalyga</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Simionescu</surname>
<given-names>A</given-names>
</string-name>, <etal>et al.</etal> (<year>2006</year>) <article-title>Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses</article-title>. <source>Am J Pathol</source>
<volume>168</volume>, <fpage>490</fpage>&#x02013;<lpage>498</lpage>.<pub-id pub-id-type="pmid">16436663</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal" id="r17">
<string-name>
<surname>Basalyga</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Simionescu</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>
<given-names>W</given-names>
</string-name>, <etal>et al.</etal> (<year>2004</year>) <article-title>Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases</article-title>. <source>Circulation</source>
<volume>110</volume>, <fpage>3480</fpage>&#x02013;<lpage>3487</lpage>.<pub-id pub-id-type="pmid">15545515</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal" id="r18">
<string-name>
<surname>Vyavahare</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Tallapragada</surname>
<given-names>S</given-names>
</string-name>, <etal>et al.</etal> (<year>2000</year>) <article-title>Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats</article-title>. <source>Am J Pathol</source>
<volume>157</volume>, <fpage>885</fpage>&#x02013;<lpage>893</lpage>.<pub-id pub-id-type="pmid">10980128</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal" id="r19">
<string-name>
<surname>Bailey</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ogle</surname>
<given-names>M</given-names>
</string-name>, <etal>et al.</etal> (<year>2001</year>) <article-title>Aluminum chloride pretreatment of elastin inhibits elastolysis by matrix metalloproteinases and leads to inhibition of elastin-oriented calcification</article-title>. <source>Am J Pathol</source>
<volume>159</volume>, <fpage>1981</fpage>&#x02013;<lpage>1986</lpage>.<pub-id pub-id-type="pmid">11733347</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal" id="r20">
<string-name>
<surname>Price</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Toroian</surname>
<given-names>D</given-names>
</string-name> &#x00026; <string-name>
<surname>Lim</surname>
<given-names>JE</given-names>
</string-name> (<year>2009</year>) <article-title>Mineralization by inhibitor exclusion: the calcification of collagen with fetuin</article-title>. <source>J Biol Chem</source>
<volume>284</volume>, <fpage>17092</fpage>&#x02013;<lpage>17101</lpage>.<pub-id pub-id-type="pmid">19414589</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal" id="r21">
<string-name>
<surname>Shearer</surname>
<given-names>MJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Newman</surname>
<given-names>P</given-names>
</string-name> (<year>2014</year>) <article-title>Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis</article-title>. <source>J Lipid Res</source>
<volume>55</volume>, <fpage>345</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">24489112</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal" id="r22">
<string-name>
<surname>Usui</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tanimura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>N</given-names>
</string-name>, <etal>et al.</etal> (<year>1990</year>) <article-title>Vitamin K concentrations in the plasma and liver of surgical patients</article-title>. <source>Am J Clin Nutr</source>
<volume>51</volume>, <fpage>846</fpage>&#x02013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">2333843</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal" id="r23">
<string-name>
<surname>Ames</surname>
<given-names>BN</given-names>
</string-name> (<year>2006</year>) <article-title>Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>103</volume>, <fpage>17589</fpage>&#x02013;<lpage>17594</lpage>.<pub-id pub-id-type="pmid">17101959</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal" id="r24">
<string-name>
<surname>Booth</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Martini</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>JW</given-names>
</string-name>, <etal>et al.</etal> (<year>2003</year>) <article-title>Dietary phylloquinone depletion and repletion in older women</article-title>. <source>J Nutr</source>
<volume>133</volume>, <fpage>2565</fpage>&#x02013;<lpage>2569</lpage>.<pub-id pub-id-type="pmid">12888638</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal" id="r25">
<string-name>
<surname>Schurgers</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Shearer</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Hamuly&#x000e1;k</surname>
<given-names>K</given-names>
</string-name>, <etal>et al.</etal> (<year>2004</year>) <article-title>Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects</article-title>. <source>Blood</source>
<volume>104</volume>, <fpage>2682</fpage>&#x02013;<lpage>2689</lpage>.<pub-id pub-id-type="pmid">15231565</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal" id="r26">
<string-name>
<surname>McCann</surname>
<given-names>JC</given-names>
</string-name> &#x00026; <string-name>
<surname>Ames</surname>
<given-names>BN</given-names>
</string-name> (<year>2009</year>) <article-title>Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?</article-title>
<source>Am J Clin Nutr</source>
<volume>90</volume>, <fpage>889</fpage>&#x02013;<lpage>907</lpage>.<pub-id pub-id-type="pmid">19692494</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal" id="r27">
<string-name>
<surname>Azoulay</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dell&#x02019;Aniello</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>TA</given-names>
</string-name>, <etal>et al.</etal> (<year>2014</year>) <article-title>Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes</article-title>. <source>Eur Heart J</source>
<volume>35</volume>, <fpage>1881</fpage>&#x02013;<lpage>1887</lpage>.<pub-id pub-id-type="pmid">24353282</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal" id="r28">
<string-name>
<surname>Akbulut</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Pavlic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Petsophonsakul</surname>
<given-names>P</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Vitamin K<sub>2</sub> needs an RDI separate from vitamin K<sub>1</sub>
</article-title>. <source>Nutrients</source>
<volume>12</volume>, E1852.</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal" id="r29">
<string-name>
<surname>Shea</surname>
<given-names>MK</given-names>
</string-name> &#x00026; <string-name>
<surname>Booth</surname>
<given-names>SL</given-names>
</string-name> (<year>2016</year>) <article-title>Concepts and controversies in evaluating vitamin K status in population-based studies</article-title>. <source>Nutrients</source>
<volume>8</volume>, E8.</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal" id="r30">
<string-name>
<surname>Brandenburg</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Reinartz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaesler</surname>
<given-names>N</given-names>
</string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>Slower progress of aortic valve calcification with vitamin K supplementation: results from a prospective interventional proof-of-concept study</article-title>. <source>Circulation</source>
<volume>135</volume>, <fpage>2081</fpage>&#x02013;<lpage>2083</lpage>.<pub-id pub-id-type="pmid">28533322</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal" id="r31">
<string-name>
<surname>Knapen</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Braam</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Drummen</surname>
<given-names>NE</given-names>
</string-name>, <etal>et al.</etal> (<year>2015</year>) <article-title>Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial</article-title>. <source>Thromb Haemost</source>
<volume>113</volume>, <fpage>1135</fpage>&#x02013;<lpage>1144</lpage>.<pub-id pub-id-type="pmid">25694037</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal" id="r32">
<string-name>
<surname>Knapen</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Drummen</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Smit</surname>
<given-names>E</given-names>
</string-name>, <etal>et al.</etal> (<year>2013</year>) <article-title>Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women</article-title>. <source>Osteoporos Int</source>
<volume>24</volume>, <fpage>2499</fpage>&#x02013;<lpage>2507</lpage>.<pub-id pub-id-type="pmid">23525894</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal" id="r33">
<string-name>
<surname>Janssen</surname>
<given-names>R</given-names>
</string-name> &#x00026; <string-name>
<surname>Vermeer</surname>
<given-names>C</given-names>
</string-name> (<year>2017</year>) <article-title>Vitamin K deficit and elastolysis theory in pulmonary elasto-degenerative diseases</article-title>. <source>Med Hypotheses</source>
<volume>108</volume>, <fpage>38</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">29055397</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal" id="r34">
<string-name>
<surname>Dofferhoff</surname>
<given-names>ASM</given-names>
</string-name>, <string-name>
<surname>Piscaer</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Schurgers</surname>
<given-names>LJ</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Reduced vitamin K status as a potentially modifiable prognostic risk factor in COVID-19</article-title>. <source>Clin Infect Dis</source> (Epublication ahead of print version 27 August 2020).</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal" id="r35">
<string-name>
<surname>Griffin</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Islam</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Wall</surname>
<given-names>D</given-names>
</string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential</article-title>. <source>Sci Rep</source>
<volume>9</volume>, <fpage>18452</fpage>.<pub-id pub-id-type="pmid">31804541</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal" id="r36">
<string-name>
<surname>Chirinos</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Sardana</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Syed</surname>
<given-names>AA</given-names>
</string-name>, <etal>et al.</etal> (<year>2018</year>) <article-title>Aldosterone, inactive matrix gla-protein, and large artery stiffness in hypertension</article-title>. <source>J Am Soc Hypertens</source>
<volume>12</volume>, <fpage>681</fpage>&#x02013;<lpage>689</lpage>.<pub-id pub-id-type="pmid">30033123</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal" id="r37">
<string-name>
<surname>Mayer</surname>
<given-names>O</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Seidlerov&#x000e1;</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bruthans</surname>
<given-names>J</given-names>
</string-name>, <etal>et al.</etal> (<year>2014</year>) <article-title>Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease</article-title>. <source>Atherosclerosis</source>
<volume>235</volume>, <fpage>162</fpage>&#x02013;<lpage>168</lpage>.<pub-id pub-id-type="pmid">24835435</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal" id="r38">
<string-name>
<surname>Schurgers</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Barreto</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Barreto</surname>
<given-names>FC</given-names>
</string-name>, <etal>et al.</etal> (<year>2010</year>) <article-title>The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report</article-title>. <source>Clin J Am Soc Nephrol</source>
<volume>5</volume>, <fpage>568</fpage>&#x02013;<lpage>575</lpage>.<pub-id pub-id-type="pmid">20133489</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal" id="r39">
<string-name>
<surname>Jespersen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>M&#x000f8;llehave</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Thuesen</surname>
<given-names>BH</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Uncarboxylated matrix Gla-protein: a biomarker of vitamin K status and cardiovascular risk</article-title>. <source>Clin Biochem</source>
<volume>83</volume>, <fpage>49</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">32422228</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal" id="r40">
<string-name>
<surname>Chen</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Sheng</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>YB</given-names>
</string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis</article-title>. <source>Eur J Nutr</source>
<volume>58</volume>, <fpage>2191</fpage>&#x02013;<lpage>2205</lpage>.<pub-id pub-id-type="pmid">31119401</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal" id="r41">
<string-name>
<surname>Parker</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Ix</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Cranenburg</surname>
<given-names>EC</given-names>
</string-name>, <etal>et al.</etal> (<year>2009</year>) <article-title>Association of kidney function and uncarboxylated matrix Gla protein: data from the Heart and Soul Study</article-title>. <source>Nephrol Dial Transplant</source>
<volume>24</volume>, <fpage>2095</fpage>&#x02013;<lpage>2101</lpage>.<pub-id pub-id-type="pmid">19204017</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal" id="r42">
<string-name>
<surname>Umeda</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Aikawa</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Libby</surname>
<given-names>P</given-names>
</string-name> (<year>2011</year>) <article-title>Liberation of desmosine and isodesmosine as amino acids from insoluble elastin by elastolytic proteases</article-title>. <source>Biochem Biophys Res Commun</source>
<volume>411</volume>, <fpage>281</fpage>&#x02013;<lpage>286</lpage>.<pub-id pub-id-type="pmid">21726534</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal" id="r43">
<string-name>
<surname>Liu</surname>
<given-names>YP</given-names>
</string-name>, <string-name>
<surname>Gu</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Thijs</surname>
<given-names>L</given-names>
</string-name>, <etal>et al.</etal> (<year>2015</year>) <article-title>Inactive matrix Gla protein is causally related to adverse health outcomes: a Mendelian randomization study in a Flemish population</article-title>. <source>Hypertension</source>
<volume>65</volume>, <fpage>463</fpage>&#x02013;<lpage>470</lpage>.<pub-id pub-id-type="pmid">25421980</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal" id="r44">
<string-name>
<surname>Riphagen</surname>
<given-names>IJ</given-names>
</string-name>, <string-name>
<surname>Keyzer</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Drummen</surname>
<given-names>NEA</given-names>
</string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>Prevalence, effects of functional vitamin K insufficiency: the PREVEND Study</article-title>. <source>Nutrients</source>
<volume>9</volume>, E1334.</mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal" id="r45">
<string-name>
<surname>Wan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>R</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title>. <source>J Virol</source>
<volume>94</volume>, e00127&#x02013;20.</mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal" id="r46">
<string-name>
<surname>Mehta</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>McAuley</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>M</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title>. <source>Lancet</source>
<volume>395</volume>, <fpage>1033</fpage>&#x02013;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">32192578</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal" id="r47">
<string-name>
<surname>He</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, <etal>et al.</etal> (<year>2006</year>) <article-title>Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS</article-title>. <source>J Pathol</source>
<volume>210</volume>, <fpage>288</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">17031779</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal" id="r48">
<string-name>
<surname>Qin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Z</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title>. <source>Clin Infect Dis</source>
<volume>71</volume>, <fpage>762</fpage>&#x02013;<lpage>768</lpage>.<pub-id pub-id-type="pmid">32161940</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal" id="r49">
<string-name>
<surname>Carsana</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sonzogni</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nasr</surname>
<given-names>A</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study</article-title>. <source>Lancet Infect Dis</source>
<volume>20</volume>, <fpage>1135</fpage>&#x02013;<lpage>1140</lpage>.<pub-id pub-id-type="pmid">32526193</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal" id="r50">
<string-name>
<surname>Beigmohammadi</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Jahanbin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Safaei</surname>
<given-names>M</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Pathological findings of postmortem biopsies from lung, heart, and liver of 7 deceased COVID-19 patients</article-title>. <source>Int J Surg Pathol</source> (Epublication ahead of print version 19 June 2020).</mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal" id="r51">
<string-name>
<surname>Liao</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>J</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title>. <source>Nat Med</source>
<volume>26</volume>, <fpage>842</fpage>&#x02013;<lpage>844</lpage>.<pub-id pub-id-type="pmid">32398875</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal" id="r52">
<string-name>
<surname>Morse</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tabib</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sembrat</surname>
<given-names>J</given-names>
</string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis</article-title>. <source>Eur Respir J</source>
<volume>54</volume>, 1802441.</mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal" id="r53">
<string-name>
<surname>Downey</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Dempster</surname>
<given-names>M</given-names>
</string-name>, <etal>et al.</etal> (<year>2007</year>) <article-title>The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis</article-title>. <source>Pediatr Pulmonol</source>
<volume>42</volume>, <fpage>216</fpage>&#x02013;<lpage>220</lpage>.<pub-id pub-id-type="pmid">17238189</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal" id="r54">
<string-name>
<surname>Huang</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Kuzmanova</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dicker</surname>
<given-names>AJ</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Serum desmosine is associated with long-term all-cause, cardiovascular mortality in bronchiectasis</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>202</volume>, <fpage>897</fpage>&#x02013;<lpage>899</lpage>.<pub-id pub-id-type="pmid">32402210</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal" id="r55">
<string-name>
<surname>Iba</surname>
<given-names>T</given-names>
</string-name> &#x00026; <string-name>
<surname>Levy</surname>
<given-names>JH</given-names>
</string-name> (<year>2020</year>) <article-title>Sepsis-induced coagulopathy and disseminated intravascular coagulation</article-title>. <source>Anesthesiology</source>
<volume>132</volume>, <fpage>1238</fpage>&#x02013;<lpage>1245</lpage>.<pub-id pub-id-type="pmid">32044801</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal" id="r56">
<string-name>
<surname>Martineau</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Jolliffe</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Hooper</surname>
<given-names>RL</given-names>
</string-name>, <etal>et al.</etal> (<year>2017</year>) <article-title>Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data</article-title>. <source>BMJ</source>
<volume>356</volume>, <fpage>i6583</fpage>.<pub-id pub-id-type="pmid">28202713</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal" id="r57">
<string-name>
<surname>Hastie</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Mackay</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>F</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Vitamin D concentrations and COVID-19 infection in UK Biobank</article-title>. <source>Diabetes Metab Syndr</source>
<volume>14</volume>, <fpage>561</fpage>&#x02013;<lpage>565</lpage>.<pub-id pub-id-type="pmid">32413819</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal" id="r58">
<string-name>
<surname>Meltzer</surname>
<given-names>DO</given-names>
</string-name>, <string-name>
<surname>Best</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Association of vitamin D deficiency and treatment with COVID-19 incidence</article-title>. <source>JAMA Netw Open</source>
<volume>3</volume>, <fpage>e2019722</fpage>.<pub-id pub-id-type="pmid">32880651</pub-id></mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="journal" id="r59">
<string-name>
<surname>D&#x02019;Avolio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Avataneo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Manca</surname>
<given-names>A</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2</article-title>. <source>Nutrients</source>
<volume>12</volume>, E1359.</mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal" id="r60">
<string-name>
<surname>Janssens</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Decramer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mathieu</surname>
<given-names>C</given-names>
</string-name>, <etal>et al.</etal> (<year>2013</year>) <article-title>Vitamin D and chronic obstructive pulmonary disease: hype or reality?</article-title>
<source>Lancet Respir Med</source>
<volume>1</volume>, <fpage>804</fpage>&#x02013;<lpage>812</lpage>.<pub-id pub-id-type="pmid">24461760</pub-id></mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal" id="r61">
<string-name>
<surname>Song</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Qi</surname>
<given-names>H</given-names>
</string-name> &#x00026; <string-name>
<surname>Wu</surname>
<given-names>C</given-names>
</string-name> (<year>2007</year>) <article-title>Effect of 1,25-(OH)2D3 (a vitamin D analogue) on passively sensitized human airway smooth muscle cells</article-title>. <source>Respirology</source>
<volume>12</volume>, <fpage>486</fpage>&#x02013;<lpage>494</lpage>.<pub-id pub-id-type="pmid">17587413</pub-id></mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal" id="r62">
<string-name>
<surname>Heulens</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Korf</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cielen</surname>
<given-names>N</given-names>
</string-name>, <etal>et al.</etal> (<year>2015</year>) <article-title>Vitamin D deficiency exacerbates COPD-like characteristics in the lungs of cigarette smoke-exposed mice</article-title>. <source>Respir Res</source>
<volume>16</volume>, <fpage>110</fpage>.<pub-id pub-id-type="pmid">26376849</pub-id></mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal" id="r63">
<string-name>
<surname>Mitchell</surname>
<given-names>F</given-names>
</string-name> (<year>2020</year>) <article-title>Vitamin-D and COVID-19: do deficient risk a poorer outcome?</article-title>
<source>Lancet Diabetes Endocrinol</source>
<volume>8</volume>, <fpage>570</fpage>.<pub-id pub-id-type="pmid">32445630</pub-id></mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal" id="r64">
<string-name>
<surname>Niederhoffer</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bobryshev</surname>
<given-names>YV</given-names>
</string-name>, <string-name>
<surname>Lartaud-Idjouadiene</surname>
<given-names>I</given-names>
</string-name>, <etal>et al.</etal> (<year>1997</year>) <article-title>Aortic calcification produced by vitamin D<sub>3</sub> plus nicotine</article-title>. <source>J Vasc Res</source>
<volume>34</volume>, <fpage>386</fpage>&#x02013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">9349732</pub-id></mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal" id="r65">
<string-name>
<surname>van Ballegooijen</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Beulens</surname>
<given-names>JWJ</given-names>
</string-name>, <string-name>
<surname>Keyzer</surname>
<given-names>CA</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Joint association of vitamins D and K status with long-term outcomes in stable kidney transplant recipients</article-title>. <source>Nephrol Dial Transplant</source>
<volume>35</volume>, <fpage>706</fpage>&#x02013;<lpage>714</lpage>.<pub-id pub-id-type="pmid">30753729</pub-id></mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal" id="r66">
<string-name>
<surname>Simes</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Viegas</surname>
<given-names>CSB</given-names>
</string-name>, <string-name>
<surname>Ara&#x000fa;jo</surname>
<given-names>N</given-names>
</string-name>, <etal>et al.</etal> (<year>2019</year>) <article-title>Vitamin K as a powerful micronutrient in aging and age-related diseases: pros and cons from clinical studies</article-title>. <source>Int J Mol Sci</source>
<volume>20</volume>, <fpage>4150</fpage>.</mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal" id="r67">
<string-name>
<surname>Speed</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Byrne</surname>
<given-names>R</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic</article-title>. <source>Thromb Res</source>
<volume>192</volume>, <fpage>73</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">32425265</pub-id></mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal" id="r68">
<string-name>
<surname>Clark</surname>
<given-names>TR</given-names>
</string-name> &#x00026; <string-name>
<surname>Burns</surname>
<given-names>S</given-names>
</string-name> (<year>2011</year>) <article-title>Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone</article-title>. <source>Am J Health Syst Pharm</source>
<volume>68</volume>, <fpage>1603</fpage>&#x02013;<lpage>1605</lpage>.<pub-id pub-id-type="pmid">21856805</pub-id></mixed-citation></ref><ref id="ref69"><label>69.</label><mixed-citation publication-type="journal" id="r69">
<string-name>
<surname>Noth</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Anstrom</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Calvert</surname>
<given-names>SB</given-names>
</string-name>, <etal>et al.</etal> (<year>2012</year>) <article-title>A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>186</volume>, <fpage>88</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">22561965</pub-id></mixed-citation></ref><ref id="ref70"><label>70.</label><mixed-citation publication-type="journal" id="r70">
<string-name>
<surname>Alagha</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Secq</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Pahus</surname>
<given-names>L</given-names>
</string-name>, <etal>et al.</etal> (<year>2015</year>) <article-title>We should prohibit warfarin in idiopathic pulmonary fibrosis</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>191</volume>, <fpage>958</fpage>&#x02013;<lpage>960</lpage>.<pub-id pub-id-type="pmid">25876206</pub-id></mixed-citation></ref><ref id="ref71"><label>71.</label><mixed-citation publication-type="journal" id="r71">
<string-name>
<surname>Hardie</surname>
<given-names>WD</given-names>
</string-name>, <string-name>
<surname>Korfhagen</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Sartor</surname>
<given-names>MA</given-names>
</string-name>, <etal>et al.</etal> (<year>2007</year>) <article-title>Genomic profile of matrix and vasculature remodeling in TGF-alpha induced pulmonary fibrosis</article-title>. <source>Am J Respir Cell Mol Biol</source>
<volume>37</volume>, <fpage>309</fpage>&#x02013;<lpage>321</lpage>.<pub-id pub-id-type="pmid">17496152</pub-id></mixed-citation></ref><ref id="ref72"><label>72.</label><mixed-citation publication-type="journal" id="r72">
<string-name>
<surname>Booth</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Hadley</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cornett</surname>
<given-names>AM</given-names>
</string-name>, <etal>et al.</etal> (<year>2012</year>) <article-title>Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>186</volume>, <fpage>866</fpage>&#x02013;<lpage>876</lpage>.<pub-id pub-id-type="pmid">22936357</pub-id></mixed-citation></ref><ref id="ref73"><label>73.</label><mixed-citation publication-type="journal" id="r73">
<string-name>
<surname>Urawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>D&#x02019;Alessandro-Gabazza</surname>
<given-names>CN</given-names>
</string-name>, <etal>et al.</etal> (<year>2016</year>) <article-title>Protein S is protective in pulmonary fibrosis</article-title>. <source>J Thromb Haemost</source>
<volume>14</volume>, <fpage>1588</fpage>&#x02013;<lpage>1599</lpage>.<pub-id pub-id-type="pmid">27172994</pub-id></mixed-citation></ref><ref id="ref74"><label>74.</label><mixed-citation publication-type="journal" id="r74">
<string-name>
<surname>Lin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>von der Th&#x000fc;sen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Isermann</surname>
<given-names>B</given-names>
</string-name>, <etal>et al.</etal> (<year>2016</year>) <article-title>High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis</article-title>. <source>J Cell Mol Med</source>
<volume>20</volume>, <fpage>2029</fpage>&#x02013;<lpage>2035</lpage>.<pub-id pub-id-type="pmid">27295971</pub-id></mixed-citation></ref><ref id="ref75"><label>75.</label><mixed-citation publication-type="journal" id="r75">
<string-name>
<surname>Tang</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bai</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, <etal>et al.</etal> (<year>2020</year>) <article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title>. <source>J Thromb Haemost</source>
<volume>18</volume>, <fpage>1094</fpage>&#x02013;<lpage>1099</lpage>.<pub-id pub-id-type="pmid">32220112</pub-id></mixed-citation></ref><ref id="ref76"><label>76.</label><mixed-citation publication-type="journal" id="r76">
<string-name>
<surname>Marlar</surname>
<given-names>RA</given-names>
</string-name> &#x00026; <string-name>
<surname>Gausman</surname>
<given-names>JN</given-names>
</string-name> (<year>2011</year>) <article-title>Protein S abnormalities: a diagnostic nightmare</article-title>. <source>Am J Hematol</source>
<volume>86</volume>, <fpage>418</fpage>&#x02013;<lpage>421</lpage>.<pub-id pub-id-type="pmid">21523802</pub-id></mixed-citation></ref><ref id="ref77"><label>77.</label><mixed-citation publication-type="book" id="r77">
<collab>Institute of Medicine (US) Panel on Micronutrients</collab> (<year>2001</year>) <source>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</source>. Washington, DC: <publisher-name>National Academies Press</publisher-name>.</mixed-citation></ref></ref-list></back></article>